Prostaglandin E2 modulates the functional responsiveness of human monocytes to chemokines

被引:38
作者
Panzer, U [1 ]
Uguccioni, M [1 ]
机构
[1] Biomed Res Inst, Bellinzona, Switzerland
关键词
chemokines; prostaglandin E-2; monocytes; inflammation;
D O I
10.1002/eji.200425226
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Prostaglandin E-2 (PGE(2)) plays an important role in the immune response by modulating the complex interactions between leukocytes and tissue cells under inflammatory conditions. PGE(2) may possibly influence pro-inflammatory effects of chemokines and chemokine receptors that are among the main regulators of directional leukocyte migration. We analyzed whether PGE2 affects chemokine receptor expression on human monocytes and their functional responsiveness to inflammatory chemokines. Expression of CCR5 on monocytes was significantly reduced, whereas CCR2 and CXCR4 expression were not affected by PGE(2). However, PGE(2) treatment significantly increased the chemotactic response of monocytes to monocyte-chemoattractant protein-1 (MCP-1), RANTES and stromal cell-derived factor-1 (SDF-1). In addition, PGE(2) induced a higher calcium mobilization and actin polymerization upon chemokine stimulation. To better characterize PGE(2) effects, we used specific agonists for the PGE(2) receptors (EP1 - EP4) characterized so far. The 11-deoxy PGE(1), an EP2 /EP4 ligand, could mimic the effects observed using PGE(2). In contrast, the EP1 agonist, sulprostone, had not effects on monocytes, indicating that the effects of PGE(2) are mediated by EP2/EP4 receptors. Monocytes acquire a higher functional responsiveness to MCP-1, RANTES and SDF-1 after exposure to PGE(2), independently of the level of chemokine receptor expression. This mechanism might enhance the local monocyte recruitment under inflammatory conditions, and suggests specific PGE(2) receptor EP2/EP4 antagonists as novel agents for the treatment of inflammatory diseases.
引用
收藏
页码:3682 / 3689
页数:8
相关论文
共 33 条
  • [1] Chemokines and leukocyte traffic
    Baggiolini, M
    [J]. NATURE, 1998, 392 (6676) : 565 - 568
  • [2] Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes
    Boie, Y
    Stocco, R
    Sawyer, N
    Slipetz, DM
    Ungrin, MD
    Neuschäfer-Rube, F
    Püschel, GP
    Metters, KM
    Abramovitz, M
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 340 (2-3) : 227 - 241
  • [3] Prostanoid receptors: Subtypes and signaling
    Breyer, RM
    Bagdassarian, CK
    Myers, SA
    Breyer, MD
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 : 661 - 690
  • [4] CHEMICAL SYNTHESIS, PURIFICATION, AND CHARACTERIZATION OF 2 INFLAMMATORY PROTEINS, NEUTROPHIL ACTIVATING PEPTIDE-1 (INTERLEUKIN-8) AND NEUTROPHIL ACTIVATING PEPTIDE-2
    CLARKLEWIS, I
    MOSER, B
    WALZ, A
    BAGGIOLINI, M
    SCOTT, GJ
    AEBERSOLD, R
    [J]. BIOCHEMISTRY, 1991, 30 (12) : 3128 - 3135
  • [5] COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283
  • [6] COLEMAN RA, 1994, PHARMACOL REV, V46, P205
  • [7] NSAIDs inhibit αVβ3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis
    Dormond, O
    Foletti, A
    Paroz, C
    Rüegg, C
    [J]. NATURE MEDICINE, 2001, 7 (09) : 1041 - 1047
  • [8] SPECIFICITY OF EXPRESSION AND EFFECTS OF EICOSANOID MEDIATORS IN NORMAL PHYSIOLOGY AND HUMAN-DISEASES
    GOETZL, EJ
    AN, SZ
    SMITH, WL
    [J]. FASEB JOURNAL, 1995, 9 (11) : 1051 - 1058
  • [9] GRIFFITHS RJ, 1999, INFLAMMATION BASIC P, P349
  • [10] Prostaglandins as modulators of immunity
    Harris, SG
    Padilla, J
    Koumas, L
    Ray, D
    Phipps, RP
    [J]. TRENDS IN IMMUNOLOGY, 2002, 23 (03) : 144 - 150